New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
| Autor: | David S.P. Tan, Stan B. Kaye, R E Miller |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Cancer Research
ARID1A Angiogenesis medicine.medical_treatment Biology carcinoma Targeted therapy clear cell medicine PTEN ovarian Animals Humans molecular Molecular Targeted Therapy PI3K/AKT/mTOR pathway targeted Ovarian Neoplasms therapy medicine.disease Oncology Clear cell carcinoma Immunology Cancer research biology.protein Adenocarcinoma Female Minireview Clear cell Adenocarcinoma Clear Cell |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Ovarian clear cell carcinomas (OCCCs) account for about 5–13% of all epithelial ovarian carcinomas in Western populations. It is characterised by resistance to conventional platinum-based chemotherapy, and new therapeutic strategies are urgently required. This article will focus on how recent discoveries have enhanced our understanding of the molecular pathogenesis of OCCCs, leading to new therapeutic opportunities. These include mutations in ARID1A, which provides a link to endometriosis, upregulation of the phosphatidylinositol 3-kinase/AKT pathway, particularly through mutations of PIK3CA and inactivation of PTEN, and increased activity of pathways involved in angiogenesis. Targeting HER2, apoptotic escape mechanisms and mismatch repair defects offer additional opportunities for treating this enigmatic tumour subtype. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|